

Supporting information

Table S1. Recoveries of Bevacizumab in 100 μ L vitreous humor over the range of 1.95 -

250 μ g.

Amount (μ g)	Recovery in each batch (%) (Mean \pm SD) (N=4)				Recovery of all batches (%)
	Batch 1	Batch 2	Batch 3	Batch 4	Overall
250.00	101.7 \pm 2.3	102.5 \pm 0.5	103.0 \pm 5.2	102.4 \pm 5.1	102.4 \pm 3.4
125.00	97.4 \pm 2.0	99.6 \pm 1.0	101.0 \pm 2.5	101.0 \pm 4.2	99.7 \pm 2.8
62.50	97.3 \pm 3.2	94.4 \pm 0.5	95.7 \pm 2.0	95.1 \pm 0.8	95.6 \pm 2.1
31.25	98.6 \pm 1.3	100.2 \pm 0.4	99.8 \pm 0.5	101.8 \pm 0.7	100.1 \pm 1.4
15.63	96.0 \pm 5.8	96.4 \pm 4.1	94.1 \pm 3.2	96.5 \pm 5.8	95.7 \pm 4.5
7.81	101.3 \pm 2.9	102.4 \pm 3.9	103.7 \pm 3.0	103.1 \pm 2.8	102.6 \pm 3.0
3.91	100.6 \pm 3.0	99.6 \pm 3.8	102.1 \pm 1.8	101.1 \pm 5.9	100.9 \pm 3.6
1.95	108.8 \pm 5.4	108.5 \pm 6.3	111.3 \pm 5.4	109.8 \pm 5.7	109.6 \pm 5.2

Table S2. Percentage of initial amount of spiked Bevacizumab in vitreous humor (ex vivo)

after incubated from 0 to 28 days at 37 °C.

Day	Percentage of Initial amount (mean ± SD) (N=4)
4 hours	86.7 ± 5.2
7	43.6 ± 4.0
14	34.2 ± 0.4
21	34.9 ± 3.2
28	35.8 ± 1.1

Table S3. Pharmacokinetics of Bevacizumab in vitreous humor after intravitreal injected

1.25 mg Bevacizumab into eyes of rabbits. The pharmacokinetics followed first order

kinetics model.

Day	Mean±SD % (n=6)
1	706.8.6±133.3
7	247.5±206.
21	58.5±10.0

$$\lambda (\text{day}^{-1}) = 0.1221$$

$$t_{1/2} (\text{days}) = 5.7$$